ViiV Healthcare’s two-drug combo non-inferior to 3-drug HIV regimen
ViiV Healthcare’s GEMINI studies showed that the 2-drug regimen (2DR) of dolutegravir plus lamivudine, appeared to have non-inferior potency in
Read more
HIV
Enzolytics and BioClonetics intent to merge sends stock parabolic
Enzolytics, Inc, a drug development company with a focus on debilitating infectious diseases, announced on September 16, the execution of
Read more